Biomarin Pharmaceutical Inc

$55.12
Market Cap 10.60B
ROE 4.4%
Gross Margin 74.6%
Debt/Equity 0.2
Current Ratio 5.8
Revenue QoQ 2.8%
EPS QoQ -0.4%
F-Score 5

About

BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Fair Value

Trading at a discount to sector peers

P/E
40.04
vs median 32.28
P/B
1.73
vs median 2.77
ROE
0.04
vs median 0.12

Decent quality with acceptable fundamentals

Large-cap company with established market presence

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics